TW202144415A - 用於調節免疫反應的材料及方法 - Google Patents

用於調節免疫反應的材料及方法 Download PDF

Info

Publication number
TW202144415A
TW202144415A TW110107163A TW110107163A TW202144415A TW 202144415 A TW202144415 A TW 202144415A TW 110107163 A TW110107163 A TW 110107163A TW 110107163 A TW110107163 A TW 110107163A TW 202144415 A TW202144415 A TW 202144415A
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
seq
cdr3
cdr2
Prior art date
Application number
TW110107163A
Other languages
English (en)
Chinese (zh)
Inventor
拉庫馬 加內桑
伊克巴爾 格雷瓦爾
桑佳亞 辛格
Original Assignee
美商健生生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/031749 external-priority patent/WO2020227457A1/en
Application filed by 美商健生生物科技公司 filed Critical 美商健生生物科技公司
Publication of TW202144415A publication Critical patent/TW202144415A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110107163A 2020-02-27 2021-02-26 用於調節免疫反應的材料及方法 TW202144415A (zh)

Applications Claiming Priority (90)

Application Number Priority Date Filing Date Title
US202062982525P 2020-02-27 2020-02-27
US202062982505P 2020-02-27 2020-02-27
US202062982574P 2020-02-27 2020-02-27
US202062982664P 2020-02-27 2020-02-27
US202062982669P 2020-02-27 2020-02-27
US202062982374P 2020-02-27 2020-02-27
US202062982478P 2020-02-27 2020-02-27
US202062982462P 2020-02-27 2020-02-27
US202062982469P 2020-02-27 2020-02-27
US202062982591P 2020-02-27 2020-02-27
US202062982548P 2020-02-27 2020-02-27
US202062982602P 2020-02-27 2020-02-27
US202062982535P 2020-02-27 2020-02-27
US202062982492P 2020-02-27 2020-02-27
US62/982,374 2020-02-27
US62/982,535 2020-02-27
US62/982,669 2020-02-27
US62/982,664 2020-02-27
US62/982,478 2020-02-27
US62/982,462 2020-02-27
US62/982,492 2020-02-27
US62/982,469 2020-02-27
US62/982,525 2020-02-27
US62/982,574 2020-02-27
US62/982,602 2020-02-27
US62/982,505 2020-02-27
US62/982,548 2020-02-27
US62/982,591 2020-02-27
US202062989010P 2020-03-13 2020-03-13
US202062989042P 2020-03-13 2020-03-13
US202062989075P 2020-03-13 2020-03-13
US202062989052P 2020-03-13 2020-03-13
US202062989057P 2020-03-13 2020-03-13
US202062989027P 2020-03-13 2020-03-13
US202062989045P 2020-03-13 2020-03-13
US202062989006P 2020-03-13 2020-03-13
US202062989068P 2020-03-13 2020-03-13
US202062989036P 2020-03-13 2020-03-13
US202062989002P 2020-03-13 2020-03-13
US202062989024P 2020-03-13 2020-03-13
US202062988996P 2020-03-13 2020-03-13
US202062989018P 2020-03-13 2020-03-13
US62/989,010 2020-03-13
US62/989,045 2020-03-13
US62/989,042 2020-03-13
US62/989,036 2020-03-13
US62/989,006 2020-03-13
US62/989,075 2020-03-13
US62/989,052 2020-03-13
US62/988,996 2020-03-13
US62/989,057 2020-03-13
US62/989,027 2020-03-13
US62/989,018 2020-03-13
US62/989,002 2020-03-13
US62/989,068 2020-03-13
US62/989,024 2020-03-13
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity
WOPCT/US20/31749 2020-05-07
US202063074937P 2020-09-04 2020-09-04
US202063074962P 2020-09-04 2020-09-04
US202063074925P 2020-09-04 2020-09-04
US202063074749P 2020-09-04 2020-09-04
US202063074839P 2020-09-04 2020-09-04
US202063074676P 2020-09-04 2020-09-04
US202063074946P 2020-09-04 2020-09-04
US202063074655P 2020-09-04 2020-09-04
US202063074735P 2020-09-04 2020-09-04
US202063074854P 2020-09-04 2020-09-04
US202063074759P 2020-09-04 2020-09-04
US202063074903P 2020-09-04 2020-09-04
US202063074700P 2020-09-04 2020-09-04
US202063074893P 2020-09-04 2020-09-04
US63/074,893 2020-09-04
US63/074,655 2020-09-04
US63/074,946 2020-09-04
US63/074,759 2020-09-04
US63/074,735 2020-09-04
US63/074,854 2020-09-04
US63/074,700 2020-09-04
US63/074,676 2020-09-04
US63/074,749 2020-09-04
US63/074,962 2020-09-04
US63/074,937 2020-09-04
US63/074,839 2020-09-04
US63/074,925 2020-09-04
US63/074,903 2020-09-04
US202063112475P 2020-11-11 2020-11-11
US202063112462P 2020-11-11 2020-11-11
US63/112,462 2020-11-11
US63/112,475 2020-11-11

Publications (1)

Publication Number Publication Date
TW202144415A true TW202144415A (zh) 2021-12-01

Family

ID=77492135

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110107163A TW202144415A (zh) 2020-02-27 2021-02-26 用於調節免疫反應的材料及方法

Country Status (10)

Country Link
US (1) US20220306739A1 (https=)
JP (1) JP2023515199A (https=)
KR (1) KR20220147631A (https=)
CN (1) CN115484981A (https=)
AU (1) AU2021225870A1 (https=)
CA (1) CA3173268A1 (https=)
IL (1) IL295897A (https=)
MX (1) MX2022010664A (https=)
TW (1) TW202144415A (https=)
WO (1) WO2021173896A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
MA55903A (fr) 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
CN115443150A (zh) 2019-12-17 2022-12-06 德克萨斯大学系统董事会 新型ddr1抗体和其用途
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
EP4237003A4 (en) 2020-10-28 2025-07-09 Janssen Biotech Inc COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
AU2023411024A1 (en) * 2022-12-23 2025-08-07 The Wistar Institute Of Anatomy And Biology Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy
TW202537974A (zh) * 2023-11-15 2025-10-01 大陸商上海盛迪醫藥有限公司 Ｔｒｇｖ９結合蛋白及其醫藥用途
WO2025220690A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞腫瘍以外の悪性腫瘍患者に有効な二重特異性抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
DK3129404T3 (da) * 2014-04-10 2026-04-20 Lava Therapeutics N V Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer
CA3297793A1 (en) * 2016-12-26 2026-03-02 Kagoshima University Antibody which binds to myelin oligodendrocyte glycoprotein
EP3743081A4 (en) * 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
CA3101271A1 (en) * 2018-05-24 2019-11-28 Janssen Biotech, Inc. Anti-cd3 antibodies and uses thereof
MA55903A (fr) * 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
JP2023517660A (ja) * 2020-03-13 2023-04-26 ヤンセン バイオテツク，インコーポレーテツド シグレック３／ｃｄ３３に結合させるための材料及び方法

Also Published As

Publication number Publication date
IL295897A (en) 2022-10-01
MX2022010664A (es) 2022-11-30
US20220306739A1 (en) 2022-09-29
JP2023515199A (ja) 2023-04-12
KR20220147631A (ko) 2022-11-03
WO2021173896A1 (en) 2021-09-02
AU2021225870A1 (en) 2022-10-20
WO2021173896A8 (en) 2022-10-06
CN115484981A (zh) 2022-12-16
CA3173268A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
TW202144415A (zh) 用於調節免疫反應的材料及方法
JP7686571B2 (ja) Ｔ細胞媒介性免疫を調節するための材料及び方法
US20210284731A1 (en) Methods and materials for modulating an immune response
JP2021521784A (ja) ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
KR20220084020A (ko) 항-tcr 델타 가변 1 항체의 치료적 용도
EP4228693A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
JP2024506682A (ja) 抗ＴＣＲδ鎖可変部１抗体
JP7847579B2 (ja) 多特異性抗ｔｃｒデルタ可変１抗体
US20260055185A1 (en) Materials and methods for modulating delta chain mediated immunity
CA3194968A1 (en) Methods and compositions for modulating beta chain mediated immunity
WO2022056197A9 (en) Immune targeting molecules and uses thereof
KR20230160254A (ko) 다중특이적 항-tcr 델타 가변 1 항체
TW202342536A (zh) 多特異性抗ＴＣＲδ可變１抗體
CN117999282A (zh) 抗TCRδ可变1抗体
EP4110390A1 (en) Materials and methods for modulating an immune response
HK40085531A (en) Materials and methods for modulating an immune response
HK40109256A (zh) 多特异性抗TCRδ可变1抗体
HK40104904A (zh) 抗TCRδ可变1抗体
HK40092859A (zh) 多特异性抗TCR δ可变1抗体
CN118234754A (zh) 多特异性抗TCRδ可变1抗体